An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy:Results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands
Background: The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, doubleblind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease (CVD)-related morbidity and mortality in 9193 patients with hypertension and left-ventricular hypertrophy (LVH). Compared with atenolol, losartan reduced the combined risk for CVD-related morbidity and mortality by 13% (P = 0.021), and reduced the risk for stroke by 25% (P = 0.001), with comparable blood pressure control in both trial arms. Objective: The aim of this s... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2007 |
Reihe/Periodikum: | Boersma , C , Carides , G W , Atthobari , J , Voors , A A & Postma , M J 2007 , ' An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy : Results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands ' , Clinical Therapeutics , vol. 29 , no. 5 , pp. 963-971 . https://doi.org/10.1016/j.clinthera.2007.05.014 |
Schlagwörter: | angiotensin-II receptor blocker / losartan / stroke / cost-effectiveness / MORTALITY / DISEASE / CARE / NEPHROPATHY / PERSPECTIVE / PREVENTION / PATTERNS / DECLINE |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26825837 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/8709f63d-351c-49a5-b443-e83782fe4c0d |